News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioCapital
Human Genome Sciences, Inc. Response to GlaxoSmithKline Press Release
June 1, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today issued the following statement in response to the GlaxoSmithKline plc (GSK) announcement regarding expiration of the Hart-Scott-Rodino waiting period:
Twitter
LinkedIn
Facebook
Email
Print
Events
GlaxoSmithKline
MORE ON THIS TOPIC
Obesity
Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA
June 27, 2025
·
5 min read
·
Heather McKenzie
IN PARTNERSHIP WITH PATSNAP
Webinar: Beyond Theory: Real-World AI Wins in Life Science R&D, Faster & Smarter
June 25, 2025
·
1 min read
·
BioSpace Insights
Rare diseases
FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent
June 24, 2025
·
3 min read
·
Heather McKenzie
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
·
2 min read
·
Jef Akst
